BCL11A

Across TCGA pan-cancer cohorts, BCL11A RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of BCL11A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where BCL11A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BCL11A is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

KIRP, KIRC, and COAD are the cancer types where BCL11A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL11A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	II,III,IV	+0.880	<.001	11	view →
KIRC	Male	All	+0.700	<.001	11	view →
COAD	All	All	+0.532	<.001	9	view →
THCA	Male	All	−0.967	<.001	8	view →
LUSC	Female	II,III,IV	+3.568	<.001	7	view →
BRCA	All	III,IV	−1.055	<.001	6	view →
LIHC	Female	All	+0.240	.007	5	view →
KICH	Female	All	−0.540	<.001	4	view →
LUAD	All	All	+0.500	<.001	3	view →
CHOL	All	All	+1.682	<.001	2	view →
PRAD	All	All	−0.863	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

BCL11A–KIRP

Open the KIRP breakdown →